Literature DB >> 6406407

Citric acid airway constriction in dogs with hyperreactive airways.

C A Hirshman, J Peters, H Downes, D Leon, R K Lynn, J Butler, J M Hanifin.   

Abstract

To understand the mechanisms underlying the bronchoconstrictor response to 10% citric acid administered for 5 min in Basenji-Greyhound (BG) dogs, we evaluated the protection afforded by atropine (0.2 and 0.4 mg/kg iv) and by aerosols of isoproterenol (1 mg/ml) and cromolyn sodium (20 mg/ml). In untreated dogs, citric acid increased pulmonary resistance by 4.6- to 11.5-fold and decreased dynamic compliance (Cdyn) to 45-55% of the control response. Isoproterenol and cromolyn sodium significantly reduced the response, whereas atropine did not. Moreover we have demonstrated in the arterial plasma of these dogs a slow-reacting substance (SRS) after, but not before, citric acid challenge. This SRS exhibits both pharmacologic properties and chemical characteristics similar to leukotrienes. We conclude that mediators of immediate-type hypersensitivity rather than reflex mechanisms play a dominant role in the production of airway constriction during citric acid (5-min) challenge in BG dogs.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6406407     DOI: 10.1152/jappl.1983.54.4.1101

Source DB:  PubMed          Journal:  J Appl Physiol Respir Environ Exerc Physiol        ISSN: 0161-7567


  3 in total

1.  Hypoxaemia after nebulised salbutamol in wheezy infants: the importance of aerosol acidity.

Authors:  J Seidenberg; Y Mir; H von der Hardt
Journal:  Arch Dis Child       Date:  1991-06       Impact factor: 3.791

2.  The effect of nedocromil sodium, sodium cromoglycate and codeine phosphate on citric acid-induced cough in dogs.

Authors:  D M Jackson
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

3.  Prevalence and effects of gastro-oesophageal reflux during spirometry in subjects undergoing reflux assessment.

Authors:  Jerry Zhou; Ming Teo; Vincent Ho; John D Brannan
Journal:  PLoS One       Date:  2020-02-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.